Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Work In Process (2022 - 2025)

InMed Pharmaceuticals has reported Work In Process over the past 4 years, most recently at $569262.0 for Q4 2025.

  • For Q4 2025, Work In Process rose 122.37% year-over-year to $569262.0; the TTM value through Dec 2025 reached $569262.0, up 122.37%, while the annual FY2025 figure was $26695.0, 13.38% down from the prior year.
  • Work In Process for Q4 2025 was $569262.0 at InMed Pharmaceuticals, up from $422798.0 in the prior quarter.
  • Over five years, Work In Process peaked at $1.7 million in Q2 2022 and troughed at $18446.0 in Q3 2024.
  • A 4-year average of $424701.1 and a median of $373256.0 in 2025 define the central range for Work In Process.
  • Biggest five-year swings in Work In Process: crashed 94.01% in 2024 and later surged 2192.09% in 2025.
  • Year by year, Work In Process stood at $798813.0 in 2022, then crashed by 76.59% to $186980.0 in 2023, then surged by 36.91% to $255992.0 in 2024, then surged by 122.37% to $569262.0 in 2025.
  • Business Quant data shows Work In Process for INM at $569262.0 in Q4 2025, $422798.0 in Q3 2025, and $26695.0 in Q2 2025.